康柏西普与雷珠单抗治疗年龄相关性黄斑变性的临床研究

目的:探讨康柏西普联合雷珠单抗治疗年龄相关性黄斑变性(AMD)的临床疗效。方法:选择2015年6月到2016年10月我院收治的60例AMD患者,按随机数字表法分为对照组和治疗组。对照组患者给予康柏西普治疗,治疗组患者给予康柏西普联合雷珠单抗治疗,两组患者均治疗3个月。评价并比较两组患者临床疗效。统计并比较两组患者治疗后的视网膜渗漏总改善率。观察并比较两组患者治疗前后最佳矫正视力和黄斑视网膜厚度。结果:治疗后,治疗组患者的视力提高率为80.00%,明显高于对照组的55.00%,差异具有统计学意义(X~2=4.104,P=0.043)。治疗后,治疗组患者的视网膜渗漏总改善率为92.50%,明显高于对照组的70.00%,差异具有统计学意义(X~2=5.294,P=0.021)。治疗前,两组患者最佳矫正视力、黄斑视网膜厚度比较差异无统计学意义(P0.05);治疗后,两组患者最佳矫正视力均明显大于治疗前,黄斑视网膜厚度均明显小于治疗前,并且治疗组均明显优于对照组,差异均具有统计学意义(P0.05)。结论:康柏西普联合雷珠单抗治疗AMD的临床疗效显著,能够明显提高视力,减轻视网膜渗漏,值得在临床上推广应用。

Clinical Study on Ranibizumab and Conbercept in the Treatment of Patients With Age-Related Macular Degeneration

ABSTRACT Objective: To study the clinical efficacy of Ranibizumab and Conbercept in the treatment of patients with age-related macular degeneration (AMD). Methods: A total of 60 patients (60 eyes) with AMD in our hospital from June 2015 to October 2016 were enrolled, the subjects were divided into control group and treatment group according to the random number table method. The control group was treated with Ranibizumab, and the treatment group were treated with Ranibizumab combined with Conbercept. The two groups were treated for 3 months. The clinical efficacy of the two groups were compared. The total improvement rate of the retinal leakage of the two groups after treatment were compared.And the best corrected visual acuity and macular thickness of the two groups before and after treatment were compared. Results: The increase rate of the vision of the treatment group was 80.00%, which was significantly higher than 55.00% of the control group, the difference was statistically significant (X²=4.104, P=0.043). The total improvement rate of the retinal leakage of the treatment group was 92.50%, which was significantly higher than 70.00% of the control group, the difference was statistically significant (X²=5.294, P=0.021). There were no significantly differences of the best corrected visual acuity and macular thickness of the two groups before treatment (P>0.05). The best corrected visual acuity of the two groups after treatment were significantly higher than before treatment, the macular thickness of the two groups after treatment were significantly lower than before treatment, and the treatment group were better than the control group, the difference was statistically significant (P<0.05). Conclusion: Ranibizumab combined with Conbercept have good clinical efficacy in the treatment of patients with AMD,which can significantly improve eyesight and reduce the leakage of the retina, it is worthy of clinical application.